Blue Lotus China New Economy Research, Blue Lotus Research Institute

Eric Wen

Blue Lotus China New Economy Research

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Thematic (Sector/Industry)

<ul>
<li>XPEV/ NIO: Xpeng and NIO's weekly sales show weakness (-)</li>
<li>9995 HK: Rumors about RemeGen's ADC to Pfizer might be returned (-)</li>
<li>TCOM/1024 HK/780 HK/3690 HK: Ctrip cooperate with Kuaishou to promote traveling products (+)</li>
</ul>


XPEV/ NIO: Xpeng and NIO's weekly sales show weakness (-)
9995 HK: Rumors about RemeGen's ADC to Pfizer might be returned (-)
TCOM/1024 HK/780 HK/3690 HK: Ctrip cooperate with Kuaishou to promote traveling products (+)


[Blue Lotus Daily]: 1211HK/XPEV/NIO/9995HK/TCOM/1024HK/780HK/3690HK

<ul>
<li>XPEV/1211 BYD: Tesla announced price reduction for Model 3 and Model Y(-)</li>
<li>TCOM/780 HK: 4Q23 inbound and outbound travel recover to 82% of 2019 level, mainly from Hong Kong and Macao(-)</li>
<li>ATAT/HTHT: National Migration Administration introduced five facilitation measures to attract foreigners to China (+)</li>
</ul>


XPEV/1211 BYD: Tesla announced price reduction for Model 3 and Model Y(-)
TCOM/780 HK: 4Q23 inbound and outbound travel recover to 82% of 2019 level, mainly from Hong Kong and Macao(-)
ATAT/HTHT: National Migration Administration introduced five facilitation measures to attract foreigners to China (+)


[Blue Lotus Daily]: NIO/LI/XPEV/TSLA/1211 HK/TCOM/780 HK/ATAT/HTHT

Asian Equities Analyst, Logistics & Transport, Tracking Traffic

Daniel Hellberg

Asian Equities Analyst, Logistics & Transport

Tracking Traffic

Focusing on Asian logistics, transportation, and travel companies

<ul>
<li>For segments we cover -- express, containers, tourism -- 2023 was challenging</li>
<li>In this note we highlight each segment's key trends and themes from 2023</li>
<li>We conclude with a look at 2023 share performance and a peak into 2024</li>
</ul>


For segments we cover -- express, containers, tourism -- 2023 was challenging
In this note we highlight each segment's key trends and themes from 2023
We conclude with a look at 2023 share performance and a peak into 2024


Key 2023 Trends & Themes in Asian Express, Containers, Tourism | Plus A Peak Into 2024

<ul>
<li>TCOM/HTHT/ATAT: China Tourism - OTA platform DAU remain lackluster, weak year end travel demand (-)</li>
<li>MNSO: Korea’s top dollar store chain Daiso buys out Japanese shareholder (-)</li>
<li>9995HK：Harbour BioMed have signed an exclusive licensing agreement with Pfizer of a mesothelin (MSLN) antibody-drug conjugate (ADC) (-) </li>
</ul>


TCOM/HTHT/ATAT: China Tourism - OTA platform DAU remain lackluster, weak year end travel demand (-)
MNSO: Korea’s top dollar store chain Daiso buys out Japanese shareholder (-)
9995HK：Harbour BioMed have signed an exclusive licensing agreement with Pfizer of a mesothelin (MSLN) antibody-drug conjugate (ADC) (-) 


[Blue Lotus Daily]: TCOM/HTHT/ATAT/MNSO/9995 HK/XPEV

<ul>
<li>BABA/TCOM: China Tourism - Singapore and China to establish mutual 30-day visa exemption (+)</li>
<li>NIO: NIO Auto to spin off its battery manufacturing business for financing (+)</li>
<li>HTHT/ATAT: China Tourism Update - Chinese Embassies abroad temporarily reduce visa fees (+)</li>
</ul>


BABA/TCOM: China Tourism - Singapore and China to establish mutual 30-day visa exemption (+)
NIO: NIO Auto to spin off its battery manufacturing business for financing (+)
HTHT/ATAT: China Tourism Update - Chinese Embassies abroad temporarily reduce visa fees (+)


[Blue Lotus Daily]: BABA/TCOM/NIO/HTHT/ATAT

China

Trip.com Group Ltd. provides online travel agency services. The Company offers mobile applications, hotel reservations, flight ticketing, package tours, corporate travel management, and train ticketing services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Trip.com (TCOM US)

[Blue Lotus Daily]: 1211HK/XPEV/NIO/9995HK/TCOM/1024HK/780HK/3690HK

Xpeng and NIO's weekly sales weaken; RemeGen's ADC to Pfizer rumors may be returned; Ctrip partners with Kuaishou to boost travel products.

Blue Lotus Research Institute

[Blue Lotus Daily]: NIO/LI/XPEV/TSLA/1211 HK/TCOM/780 HK/ATAT/HTHT

Tesla reduces prices for Model 3 and Model Y; Travel recovers to 82% of 2019 levels in Hong Kong and Macao; China introduces measures to attract...

Blue Lotus Research Institute

Key 2023 Trends & Themes in Asian Express, Containers, Tourism | Plus A Peak Into 2024

In this insight we look at the important trends and themes we've covered this year in the express, containers, and tourism sectors. We also...

Tracking Traffic

[Blue Lotus Daily]: TCOM/HTHT/ATAT/MNSO/9995 HK/XPEV

China's tourism OTA platform sees low user activity and weak year-end travel demand. Korea's Daiso acquires Japanese shareholder. Harbour BioMed...

Blue Lotus Research Institute

[Blue Lotus Daily]: BABA/TCOM/NIO/HTHT/ATAT

China and Singapore agree to a 30-day visa exemption for tourism, NIO Auto plans to separate its battery manufacturing for funding, and Chinese...

Blue Lotus Research Institute

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

[Blue Lotus Daily]: 1211HK/XPEV/NIO/9995HK/TCOM/1024HK/780HK/3690HK

​Xpeng and NIO's weekly sales weaken; RemeGen's ADC to Pfizer rumors may be returned; Ctrip partners with Kuaishou to boost travel products.

Blue Lotus Research Institute

[Blue Lotus Daily]: NIO/LI/XPEV/TSLA/1211 HK/TCOM/780 HK/ATAT/HTHT

​Tesla reduces prices for Model 3 and Model Y; Travel recovers to 82% of 2019 levels in Hong Kong and Macao; China introduces measures to attract...

Blue Lotus Research Institute

Key 2023 Trends & Themes in Asian Express, Containers, Tourism | Plus A Peak Into 2024

In this insight we look at the important trends and themes we've covered this year in the express, containers, and tourism sectors. We also...

Tracking Traffic

[Blue Lotus Daily]: TCOM/HTHT/ATAT/MNSO/9995 HK/XPEV

​China's tourism OTA platform sees low user activity and weak year-end travel demand. Korea's Daiso acquires Japanese shareholder. Harbour BioMed...

Blue Lotus Research Institute

[Blue Lotus Daily]: BABA/TCOM/NIO/HTHT/ATAT

​China and Singapore agree to a 30-day visa exemption for tourism, NIO Auto plans to separate its battery manufacturing for funding, and Chinese...

Blue Lotus Research Institute

Xpeng and NIO's weekly sales weaken; RemeGen's ADC to Pfizer rumors may be returned; Ctrip partners with Kuaishou to boost travel products.

Tesla reduces prices for Model 3 and Model Y; Travel recovers to 82% of 2019 levels in Hong Kong and Macao; China introduces measures to attract...

China's tourism OTA platform sees low user activity and weak year-end travel demand. Korea's Daiso acquires Japanese shareholder. Harbour BioMed...

China and Singapore agree to a 30-day visa exemption for tourism, NIO Auto plans to separate its battery manufacturing for funding, and Chinese...